Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.EnteroMedics has announced positive interim clinical results for Maestro RF2 System, which is currently being evaluated in 33 obese patients outside the US in the VBLOC-RF2 clinical feasibility study of the company's proprietary VBLOC vagal blocking therapy.
Subscribe to our email newsletter
The most recent follow-up of nine RF2 patients, among the earliest patients implanted in the VBLOC-RF2 trial, showed an excess weight loss (EWL) of 29.5% at nine months of VBLOC therapy. The most recent results for the prior follow-up periods demonstrate an EWL of 10.2% in 32 RF2 patients at one month, an EWL of 17.5% in 26 RF2 patients at three months and an EWL of 22.1% in 21 RF2 patients at six months of VBLOC therapy.
Mark Knudson, president and CEO of EnteroMedics, said: “We are encouraged by these interim weight loss data and the safety profile of our Maestro RF2 System. The results continue to support VBLOC therapy as a meaningful choice for physicians and their patients seeking sustainable weight loss.”